



DOCKET NO.: GLIS-0144

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Kuei-Ying Lin and Mark D. Matteucci

Patent No.: 6,028,183

Application No.: 10/080,074

Filing Date: February 21, 2002

For: Pyrimidine Derivatives And Oligonucleotides Containing The Same

Confirmation No.: 8556

Issued: February 22, 2000

Group Art Unit: 1623

Examiner: Howard V. Owens, Jr.

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL REISSUE DECLARATION

A. Declaration by Inventor(s):

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and

I verily believe that I am the original, first and sole inventor (if only one name is listed below), or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed in letters patent number granted on and in the foregoing specification and for which invention I solicit a reissue patent;

B. Declaration by Assignee:

I, B. Lynne Parshall, of Isis Pharmaceuticals, Inc. 2292 Faraday Avenue, Carlsbad, California 92008, declare that the entire title to letters patent number 6,028,183 for "Pyrimidine Derivatives and Oligonucleotides Containing The Same," granted on February 22, 2000, to Isis Pharmaceuticals, Inc. is 100% vested, that I believe said named inventor(s) to be an original, first and sole inventor (if only one name is listed) or an original, first and part inventor (if plural names are listed) of the subject matter that is described and claimed in the aforesaid letters patent and in the foregoing specification and for which invention I solicit a reissue patent.

ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims.

I acknowledge the duty to disclose all information known to be material to the patentability of this application in accordance with 37 C.F.R. § 1.56.

- In compliance with this duty attached herewith is an Information Disclosure Statement in accordance with 37 C.F.R. § 1.97.

STATEMENT AS TO ADDITIONAL ERRORS UNDER 37 C.F.R. §1.175(b)(1)

In accordance with 37 C.F.R. 1.175(b)(1), applicant states that all errors being corrected in this reissue application which are not covered by the original reissue declaration in said application arose without deceptive intention on the part of the applicant.

Note: The PTO commentary as to the revision of Rule 175 states: "a supplemental oath can now be filed prior to allowance that generally states that all errors being corrected, which were not covered by the original or a previously submitted oath, arose without deceptive intent."

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name: Kuei-Ying Lin	Signature
Mailing Address: 4774 Canvasback Common Fremont, CA 94555	Date of Signature:
City/State of Actual Residence: Fremont, California	Citizenship: United States

Name: Mark D. Matteucci	Signature
Mailing Address: 135 Fawn Lane Portolla Valley, CA 94028	Date of Signature:
City/State of Actual Residence: Portolla Valley, California	Citizenship:

Note: Even though inventor(s) do not sign, complete above information for inventor(s).

By assignee or person authorized to sign on behalf of assignee:

Note: Execute only if inventors did not sign.

Date: 11-19-04

By:

B. Lynne Parshall
Executive Vice President and
Chief Financial Officer
Signature of assignee or person
authorized to sign on behalf of assignee
with typed name and title